Experimental Alzheimer’s drug lowers tau protein levels in early disease

Researchers announced on Tuesday that an experimental drug can slow the progression of early‑stage Alzheimer’s disease by reducing the levels of tau, a protein that forms neurofibrillary tangles in the brains of affected patients. The study, published in a peer‑reviewed journal, followed a cohort of individuals with mild cognitive impairment who received the investigational therapy over a 12‑month period. Compared with placebo, the treatment group showed a statistically significant decline in tau concentrations measured in cerebrospinal fluid, along with modest improvements on memory and executive function tests.

The findings represent a departure from current Alzheimer’s therapies, which primarily target amyloid‑beta plaques. By addressing tau pathology, the drug offers a new mechanistic approach that could complement existing strategies. The investigators noted that the safety profile was acceptable and that the drug’s pharmacokinetics allowed for once‑daily dosing. However, they cautioned that larger, longer‑term trials are required to confirm the clinical benefits and to determine whether the tau‑lowering effect translates into meaningful disease modification.

If subsequent studies confirm these early results, the therapy could broaden the therapeutic arsenal against Alzheimer’s disease and provide a new option for patients in the earliest stages of the condition. The research team plans to initiate Phase III trials later this year, aiming to evaluate the drug’s efficacy in a larger, more diverse population and to assess its impact on disease progression over multiple years.